{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR3+Receptor",
    "query": {
      "condition": "FGFR3 Receptor"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 16,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=FGFR3+Receptor&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:38:29.963Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06164951",
      "title": "A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib 0.25 mg/kg/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator 0.25 mg/kg/day",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "3 Years to 17 Years"
      },
      "enrollment_count": 114,
      "start_date": "2023-11-10",
      "completion_date": "2025-12-18",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 7,
      "location_summary": "San Francisco, California • Aurora, Colorado • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06164951"
    },
    {
      "nct_id": "NCT04265651",
      "title": "Study of Infigratinib in Children With Achondroplasia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib 0.016 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib 0.032 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib 0.064 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib 0.128 mg/kg",
          "type": "DRUG"
        },
        {
          "name": "Infigratinib 0.25 mg/kg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "11 Years",
        "sex": "ALL",
        "summary": "3 Years to 11 Years"
      },
      "enrollment_count": 84,
      "start_date": "2020-03-10",
      "completion_date": "2024-10-21",
      "has_results": false,
      "last_update_posted_date": "2025-10-22",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 5,
      "location_summary": "Oakland, California • Wilmington, Delaware • Baltimore, Maryland + 2 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265651"
    },
    {
      "nct_id": "NCT05145010",
      "title": "Extension Study of Infigratinib in Children With Achondroplasia (ACH)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Achondroplasia"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "3 Years to 18 Years"
      },
      "enrollment_count": 300,
      "start_date": "2021-12-06",
      "completion_date": "2032-02-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-31",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 8,
      "location_summary": "Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05145010"
    },
    {
      "nct_id": "NCT05544552",
      "title": "Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Locally Advanced Urothelial Carcinoma",
        "Metastatic Urothelial Carcinoma",
        "Solid Tumor",
        "Urothelial Carcinoma",
        "Solid Tumor, Adult",
        "Bladder Cancer",
        "Non-muscle-invasive Bladder Cancer",
        "FGFR3 Gene Mutation",
        "FGFR3 Gene Alteration",
        "Advanced Solid Tumor",
        "Advanced Urothelial Carcinoma",
        "Urinary Tract Cancer",
        "Urinary Tract Tumor",
        "Urinary Tract Carcinoma"
      ],
      "interventions": [
        {
          "name": "TYRA-300",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tyra Biosciences, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 310,
      "start_date": "2022-11-22",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-12",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 7,
      "location_summary": "Boston, Massachusetts • Worchester, Massachusetts • New York, New York + 4 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Worchester",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05544552"
    },
    {
      "nct_id": "NCT01752920",
      "title": "Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "Derazantinib low dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib middle dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib high dose range",
          "type": "DRUG"
        },
        {
          "name": "Derazantinib at recommended phase 2 dose (RP2D)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Basilea Pharmaceutica",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2012-12-10",
      "completion_date": "2018-08-28",
      "has_results": true,
      "last_update_posted_date": "2023-06-05",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 8,
      "location_summary": "Scottsdale, Arizona • Atlanta, Georgia • Detroit, Michigan + 5 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Las Vegas",
          "state": "Nevada"
        },
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01752920"
    },
    {
      "nct_id": "NCT06410976",
      "title": "Prospective Clinical Assessment Study in Children With Hypochondroplasia",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypochondroplasia"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Months",
        "maximum_age": "16 Years",
        "sex": "ALL",
        "summary": "30 Months to 16 Years"
      },
      "enrollment_count": 150,
      "start_date": "2024-06-05",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 8,
      "location_summary": "Oakland, California • Aurora, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Columbia",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06410976"
    },
    {
      "nct_id": "NCT04197986",
      "title": "Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Upper Tract Urothelial Carcinomas",
        "Urothelial Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Infigratinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "QED Therapeutics, a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2020-03-11",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-03-13",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 47,
      "location_summary": "Tucson, Arizona • Duarte, California • Loma Linda, California + 39 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04197986"
    },
    {
      "nct_id": "NCT01732107",
      "title": "Dovitinib in BCG Refractory Urothelial Carcinoma With FGFR3 Mutations or Over-expression",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Dovitinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Noah Hahn, M.D.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2013-03",
      "completion_date": "2017-03-06",
      "has_results": true,
      "last_update_posted_date": "2022-07-11",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Baltimore, Maryland • Rockledge, Pennsylvania",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rockledge",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01732107"
    },
    {
      "nct_id": "NCT02272998",
      "title": "Ponatinib for Patients Whose Advanced Solid Tumor Cancer Has Activating Mutations Involving the Following Genes: FGFR1, FGFR2, FGFR3, FGFR4, RET, KIT.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Neoplasm"
      ],
      "interventions": [
        {
          "name": "ponatinib hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Sameek Roychowdhury",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2015-02-24",
      "completion_date": "2022-11-17",
      "has_results": true,
      "last_update_posted_date": "2025-03-24",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 2,
      "location_summary": "Ann Arbor, Michigan • Columbus, Ohio",
      "locations": [
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02272998"
    },
    {
      "nct_id": "NCT02529553",
      "title": "A Study of LY3076226 in Participants With Advanced or Metastatic Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Cancer",
        "Metastatic Cancer"
      ],
      "interventions": [
        {
          "name": "LY3076226",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-09",
      "completion_date": "2018-03-28",
      "has_results": true,
      "last_update_posted_date": "2020-04-17",
      "last_synced_at": "2026-05-22T05:38:29.963Z",
      "location_count": 3,
      "location_summary": "Philadelphia, Pennsylvania • Charleston, South Carolina • San Antonio, Texas",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02529553"
    }
  ]
}